Valeant Pharmaceuticals’ NDA for the investigational drug retigabine has been accepted for review by the FDA. Retigabine is a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures.

Additionally, the company’s MAA was successfully validated by the EMEA on November 17, 2009. The filings were submitted on October 30, 2009.

News from our sister sites